Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system

被引:111
|
作者
Berget, Cari [1 ]
Messer, Laurel H. [1 ]
Vigers, Tim [2 ]
Frohnert, Brigitte I. [1 ]
Pyle, Laura [1 ,2 ]
Wadwa, R. Paul [1 ]
Driscoll, Kimberly A. [1 ,3 ]
Forlenza, Gregory P. [1 ]
机构
[1] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Anschutz Campus, Aurora, CO 80045 USA
[2] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA
[3] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA
关键词
pediatrics; artificial pancreas; automated insulin delivery; continuous glucose monitor; INSULIN DELIVERY-SYSTEM; QUALITY-OF-LIFE; PROBLEM AREAS; TYPE-1; ADOLESCENTS;
D O I
10.1111/pedi.12962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To describe glycemic and psychosocial outcomes in youth with type 1 diabetes using a hybrid closed loop (HCL) system. Subjects Youth with type 1 diabetes (2-25 years) starting the 670G HCL system for their diabetes care were enrolled in an observational study. Methods Prospective data collection occurred during routine clinical care and included glycemic variables (sensor time in range [70-180 mg/dL], HbA1c), and psychosocial variables (Hypoglycemia Fear Survey [HFS]; Problem Areas in Diabetes [PAID]). Mixed models were used to analyze change across time. Results Ninety-two youth (mean age 15.7 +/- 3.6 years, 50% female, HbA1c 8.8% +/- 1.8%) started HCL for their diabetes care. Youth used Auto Mode 65.5% +/- 3.0% of the time at month 1, which decreased to 51.2% +/- 3.4% at month 6 (P = .001). Sensor time in range increased from 50.7% +/- 1.8% at baseline to 56.9% +/- 2.1% at 6 months (P = .007). HbA1c decreased from 8.7% +/- 0.2% at baseline to 8.4% +/- 0.2% after 6 months of use (P <= .0001), with the greatest HbA1c decline in participants with high baseline HbA1c. Increased percent time in auto mode was associated with lower HbA1c (P = .02). Thirty percent of youth discontinued HCL in the first 6 months of use. There were no changes in the HFS or PAID scores across time. Conclusions HCL use is associated with improved glycemic control and no change in psychosocial outcomes in this clinical sample. The decline in HCL use across time suggests that youth experience barriers in sustaining use of HCL. Further research is needed to understand reasons for HCL discontinuation and determine intervention strategies.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
  • [21] SIX MONTHS IN ADVANCED HYBRID CLOSED LOOP SYSTEM IN THE REAL WORLD: PSYCHOSOCIAL OUTCOMES IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES
    Jalilova, A.
    Pilan, B. Senturk
    Demir, G.
    Ozbaran, B.
    Kose, S. G.
    Ozen, S.
    Darcan, S.
    Goksen, D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A264 - A264
  • [22] A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G
    Weinzimer, Stuart A.
    Bailey, Ryan J.
    Bergenstal, Richard M.
    Nimri, Revital
    Beck, Roy W.
    Schatz, Desmond
    Ambler-Osborn, Louise
    Schweiger, Darja Smigoc
    von dem Berge, Thekla
    Sibayan, Judy
    Johnson, Mary L.
    Calhoun, Peter
    Phillip, Moshe
    Criego, Amy
    Carlson, Anders
    Martens, Thomas
    Beasley, Shannon
    Whipple, Diane
    Hyatt, Jamie
    Punel, Alina
    Grieme, Aimee
    Thomas, Lee Ann
    LaFrance, Amy
    Hasledalen, Caitlin
    Laffel, Lori
    Isganaitis, Elvira
    Freiner, Emily
    Desrochers, Hannah
    Turcotte, Christine
    Naik, Nisha
    Roethke, Lindsay
    Fisher, Margaret
    Nevo, Michal
    Bello, Rachel
    Hamou, Alona
    Hermon, Orna
    Horesh, Orit
    Mantzuri, Galit Shiovitch
    Drotz, Irit
    Yehiel, Nava
    Naveh, Rachel
    Haller, Michael
    Albanese-O'Neill, Anastasia
    Sheehan, Eleni
    Sheehan, Eleni
    Smith, Madison
    Jacobsen, Laura
    Adams, Janey
    Hosford, Jennifer
    Whyte, Loren
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (08) : 573 - 582
  • [23] Real-World Efficacy of the Hybrid Closed-Loop System
    Usoh, Chinenye O.
    Johnson, Crystal Paige
    Speiser, Jaime L.
    Bundy, Richa
    Dharod, Ajay
    Aloi, Joseph A.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2022, 16 (03): : 659 - 662
  • [24] Real-world use of the MiniMed™ 670G system by patients with type 1 or type 2 diabetes
    Lee, S. W.
    Shin, J.
    Chen, X.
    Nguyen, M. -H.
    Cordero, T. L.
    Kaufman, F. R.
    DIABETOLOGIA, 2018, 61 : S394 - S394
  • [25] Postprandial Response in Children Using the MiniMed™ 670G System
    Grosman, Benyamin
    Roy, Anirban
    Wu, Di
    Parikh, Neha
    Lee, Scott W.
    Kaufman, Francine R.
    DIABETES, 2018, 67
  • [26] Clinical Experience with the MiniMed 670G System in Children, Adolescents, and Young Adults with Type 1 Diabetes
    Henson, Carlo J.
    Barnes, Timothy L.
    Nickel, Amanda J.
    Abuzzahab, M. Jennifer
    Kyllo, Jennifer
    Gandrud, Laura M.
    DIABETES, 2018, 67
  • [27] Real-World Data from the MiniMed™ 670G System Commercial Launch-Patients Previously Using MDI Therapy
    Gopalakrishnan, Shweta
    Agrawal, Pratik
    Stone, Michael
    Fogel, Catherine
    Lee, Scott W.
    DIABETES, 2018, 67
  • [28] Real-World Evidence Analysis of a Hybrid Closed-Loop System
    Alwan, Heba
    Wilinska, Malgorzata E.
    Ruan, Yue
    Da Silva, Julien
    Hovorka, Roman
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2025, 19 (02): : 385 - 389
  • [29] Real-World Evidence Analysis of a Hybrid Closed-Loop System
    Alwan, Heba
    Wilinska, Malgorzata E.
    Ruan, Yue
    Da Silva, Julien
    Hovorka, Roman
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023,
  • [30] Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use
    Berget, Cari
    Akturk, Halis Kaan
    Messer, Laurel H.
    Vigers, Timothy
    Pyle, Laura
    Snell-Bergeon, Janet
    Driscoll, Kimberly A.
    Forlenza, Gregory P.
    DIABETES OBESITY & METABOLISM, 2021, 23 (09): : 2048 - 2057